197 related articles for article (PubMed ID: 12600826)
1. The antimicrobial activity of the cathelicidin LL37 is inhibited by F-actin bundles and restored by gelsolin.
Weiner DJ; Bucki R; Janmey PA
Am J Respir Cell Mol Biol; 2003 Jun; 28(6):738-45. PubMed ID: 12600826
[TBL] [Abstract][Full Text] [Related]
2. Anionic poly(amino acid)s dissolve F-actin and DNA bundles, enhance DNase activity, and reduce the viscosity of cystic fibrosis sputum.
Tang JX; Wen Q; Bennett A; Kim B; Sheils CA; Bucki R; Janmey PA
Am J Physiol Lung Cell Mol Physiol; 2005 Oct; 289(4):L599-605. PubMed ID: 15964901
[TBL] [Abstract][Full Text] [Related]
3. Release of the antimicrobial peptide LL-37 from DNA/F-actin bundles in cystic fibrosis sputum.
Bucki R; Byfield FJ; Janmey PA
Eur Respir J; 2007 Apr; 29(4):624-32. PubMed ID: 17215317
[TBL] [Abstract][Full Text] [Related]
4. Resistance of the antibacterial agent ceragenin CSA-13 to inactivation by DNA or F-actin and its activity in cystic fibrosis sputum.
Bucki R; Sostarecz AG; Byfield FJ; Savage PB; Janmey PA
J Antimicrob Chemother; 2007 Sep; 60(3):535-45. PubMed ID: 17584802
[TBL] [Abstract][Full Text] [Related]
5. Actin limits enhancement of nanoparticle diffusion through cystic fibrosis sputum by mucolytics.
Broughton-Head VJ; Smith JR; Shur J; Shute JK
Pulm Pharmacol Ther; 2007; 20(6):708-17. PubMed ID: 17055310
[TBL] [Abstract][Full Text] [Related]
6. The role of DNA and actin polymers on the polymer structure and rheology of cystic fibrosis sputum and depolymerization by gelsolin or thymosin beta 4.
Kater A; Henke MO; Rubin BK
Ann N Y Acad Sci; 2007 Sep; 1112():140-53. PubMed ID: 17496063
[TBL] [Abstract][Full Text] [Related]
7. Antibacterial activities of rhodamine B-conjugated gelsolin-derived peptides compared to those of the antimicrobial peptides cathelicidin LL37, magainin II, and melittin.
Bucki R; Pastore JJ; Randhawa P; Vegners R; Weiner DJ; Janmey PA
Antimicrob Agents Chemother; 2004 May; 48(5):1526-33. PubMed ID: 15105101
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of Pulmozyme activity in purulent sputum by combination with poly-aspartic acid or gelsolin.
Bucki R; Cruz K; Pogoda K; Eggert A; Chin L; Ferrin M; Imbesi G; Hadjiliadis D; Janmey PA
J Cyst Fibros; 2015 Sep; 14(5):587-93. PubMed ID: 25682700
[TBL] [Abstract][Full Text] [Related]
9. Bactericidal activities of cathelicidin LL-37 and select cationic lipids against the hypervirulent Pseudomonas aeruginosa strain LESB58.
Wnorowska U; Niemirowicz K; Myint M; Diamond SL; Wróblewska M; Savage PB; Janmey PA; Bucki R
Antimicrob Agents Chemother; 2015 Jul; 59(7):3808-15. PubMed ID: 25870055
[TBL] [Abstract][Full Text] [Related]
10. LL-37 complexation with glycosaminoglycans in cystic fibrosis lungs inhibits antimicrobial activity, which can be restored by hypertonic saline.
Bergsson G; Reeves EP; McNally P; Chotirmall SH; Greene CM; Greally P; Murphy P; O'Neill SJ; McElvaney NG
J Immunol; 2009 Jul; 183(1):543-51. PubMed ID: 19542465
[TBL] [Abstract][Full Text] [Related]
11. Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis.
Alipour M; Suntres ZE; Halwani M; Azghani AO; Omri A
PLoS One; 2009 May; 4(5):e5724. PubMed ID: 19479000
[TBL] [Abstract][Full Text] [Related]
12. Interaction of the gelsolin-derived antibacterial PBP 10 peptide with lipid bilayers and cell membranes.
Bucki R; Janmey PA
Antimicrob Agents Chemother; 2006 Sep; 50(9):2932-40. PubMed ID: 16940084
[TBL] [Abstract][Full Text] [Related]
13. Cathelicidin peptides inhibit multiply antibiotic-resistant pathogens from patients with cystic fibrosis.
Saiman L; Tabibi S; Starner TD; San Gabriel P; Winokur PL; Jia HP; McCray PB; Tack BF
Antimicrob Agents Chemother; 2001 Oct; 45(10):2838-44. PubMed ID: 11557478
[TBL] [Abstract][Full Text] [Related]
14. P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients.
Sajjan US; Tran LT; Sole N; Rovaldi C; Akiyama A; Friden PM; Forstner JF; Rothstein DM
Antimicrob Agents Chemother; 2001 Dec; 45(12):3437-44. PubMed ID: 11709321
[TBL] [Abstract][Full Text] [Related]
15. Gelsolin activates DNase I in vitro and cystic fibrosis sputum.
Davoodian K; Ritchings BW; Ramphal R; Bubb MR
Biochemistry; 1997 Aug; 36(32):9637-41. PubMed ID: 9289015
[TBL] [Abstract][Full Text] [Related]
16. DNA and actin bind and inhibit interleukin-8 function in cystic fibrosis sputa: in vitro effects of mucolytics.
Perks B; Shute JK
Am J Respir Crit Care Med; 2000 Nov; 162(5):1767-72. PubMed ID: 11069810
[TBL] [Abstract][Full Text] [Related]
17. Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin.
Vasconcellos CA; Allen PG; Wohl ME; Drazen JM; Janmey PA; Stossel TP
Science; 1994 Feb; 263(5149):969-71. PubMed ID: 8310295
[TBL] [Abstract][Full Text] [Related]
18. Actin filaments mediate DNA fiber formation in chronic inflammatory airway disease.
Sheils CA; Käs J; Travassos W; Allen PG; Janmey PA; Wohl ME; Stossel TP
Am J Pathol; 1996 Mar; 148(3):919-27. PubMed ID: 8774146
[TBL] [Abstract][Full Text] [Related]
19. Bactericidal activity of mammalian cathelicidin-derived peptides.
Travis SM; Anderson NN; Forsyth WR; Espiritu C; Conway BD; Greenberg EP; McCray PB; Lehrer RI; Welsh MJ; Tack BF
Infect Immun; 2000 May; 68(5):2748-55. PubMed ID: 10768969
[TBL] [Abstract][Full Text] [Related]
20. Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applications.
Deslouches B; Islam K; Craigo JK; Paranjape SM; Montelaro RC; Mietzner TA
Antimicrob Agents Chemother; 2005 Aug; 49(8):3208-16. PubMed ID: 16048927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
